

2020 Taipei International Breast Cancer Symposium

7F, Taipei Nangang Exhibition Center, Hall 2

Sat., November 7, 2020

Time	Topic	Speaker	Moderator
08:15-08:20	Opening Remarks	Ling-Ming Tseng	
08:20-08:30		Shih-Chung Chen	
Progress and Challenge			
08:30-09:10	Lessons learned in the treatment of breast cancer over the past five decades	Gabriel Hortobagyi	Ling-Ming Tseng
Targeted Therapy 1			
09:10-09:15	Case presentation, and vote	Jiun-I Lai	
09:15-09:45	Use of tyrosine kinase inhibitors in the treatment of HER2-positive breast cancer	Adam Brufsky	Hwei-Chung Wang
09:45-10:15	The role of PI3K inhibitor in HR+, HER2- advanced breast cancer and how to optimize the treatment	Ingrid Mayer	Tsu-Yi Chao
10:15-10:40	Panel discussion	Adam Brufsky / Ingrid Mayer/Wen-Ling Kuo Chih-Chiang Hung /Ying-Wen Su	
10:40-11:00	Coffee Break		
11:00-11:30	PARP inhibitors and immune checkpoint therapy on breast cancer	Mien-Chie Hung	King-Jen Chang Hsien-Tang Yeh
11:30-12:00	Ethnic difference in breast cancer treatment	Hiroji Iwata	Shyr-Ming Sheen-Chen
12:00-12:30	Cracking the genetic codes to unlock treatment options: a lesson from CGP on real-world cases	Chien-Feng Li	Fang-Ming Chen
I/O and Chemotherapy			
12:30-13:10	Luncheon Symposium Combination strategies of checkpoint immunotherapy and chemotherapy in metastatic TNBC	Ming-Shen Dai	Hsien-Kun Chang
13:10-13:20	Break		
13:20-13:25	Case presentation, and vote	Yi-Fang Tsai	
13:25-13:55	Raise the bar higher: evolving treatment landscape in neoadjuvant TNBC with immunotherapy	Ming-Shen Dai	Jyh-Cherng Yu
13:55-14:25	Future roles of immune checkpoint inhibitors in breast cancer treatment- evolving integration from metastatic to peri-operative treatments	Chun-Yu Liu	Ming-Feng Hou
14:25-14:55	The transforming advancement in mBC treatment in 2020	Peter Schmid	Yen-Shen Lu
14:55-15:15	Panel discussion	Ming-Shen Dai / Chun-Yu Liu Peter Schmid / Wen-Hung Kuo Liang-Chih Liu / Dwan-Ying Chang	
15:15-15:35	Coffee Break		
Targeted Therapy II			
15:35-15:40	Case presentation, and vote	Dwan-Ying Chang	
15:40-16:10	HER2-positive eBC treatment overview- aim for cure with advanced treatment strategy	Luca Gianni	Chiun-Sheng Huang
16:10-16:40	Bringing biosimilars to life: clinical experience sharing	Marc Thill	Su-Shun Lo
16:40-17:10	Two decades after BRCA discovery: hereditary breast cancer, homologous recombination deficiency and PARP inhibitor	Po-Han Lin	Ching-Hung Lin
17:10-17:40	DDR science and early BRCA testing	Shani Paluch Shimon	Shin-Cheh Chen
17:40-18:00	Panel discussion	Luca Gianni/ Marc Thill/ Po-Han Lin Shani Paluch Shimon / Yuan-Ching Chang Huan-Ming Hsu / Wei-Pang Chung	

2020 Taipei International Breast Cancer Symposium

7F, Taipei Nangang Exhibition Center, Hall 2

Sun., November 8, 2020

Time	Topic	Speaker	Moderator
08:05-08:55	Abstract oral presentation	Ling-Ming Tseng	
08:55-09:15	Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets	Chi-Cheng Huang	Ming-Feng Hou
09:15-09:35	Unique characteristics of breast cancer in East Asia	Yen-Shen Lu	
Luminal ABC			
09:35-09:40	Case presentation, and vote	Lo Chiao	
09:40-10:10	Recent advancement of POST CDK 4/6 inhibitor treatment strategy in HR+ HER2- metastatic breast cancer	Naoto Ueno	Chiun-Sheng Huang
10:10-10:40	CDK4/6 inhibitor and immune modulation	Shom Goel	Ming-Hsin Yeh
10:40-11:00	Coffee Break		
11:00-11:30	Evolving evidence on the uniqueness of premenopausal breast cancer	Ching-Hung Lin	Dar-Ren Chen
11:30-12:00	Envision a longer future: uncover the new era of endocrine treatments in HR+ HER2- metastatic breast cancer	Ta-Chung Chao	Kun-Ming Rau
12:00-12:20	Panel discussion	Naoto Ueno / Shom Goel / Ching-Hung Lin Ta-Chung Chao / Ming-Yang Wang Shih-Che Shen / Chun-Yu Liu	
12:20-13:00	Luncheon Symposium New developments in chemotherapy-based treatment for early breast cancer	Chin-Sheng Hung	Dah-Cherng Yeh
13:00-13:20	Break		
Special Lecture			
13:20-13:50	Artificial intelligence in breast cancer medicine	Kung-Hao Liang	Fiona Tsui-Fen Cheng Chao-Ming Hung
13:50-14:20	Clinical breast cancer practice during COVID-19 pandemic	Hsiu-Hsi Chen	King-Jen Chang Chen-Hsiang Chang
14:20-14:50	COVID19: ensuring the quality, resiliency, and continuity of breast cancer care during a pandemic	Chieh-Han Chuang	Fang-Ming Chen Chin-Hua Tsai
14:50-15:10	Coffee Break		
Local Regional Therapy			
15:10-15:30	Lessons learned from nipple-sparing mastectomy with oncologic outcomes	Shin-Cheh Chen	Dar-Ren Chen Yao-Lung Kuo
15:30-15:50	Locoregional management after neoadjuvant chemotherapy	Jeong Eon Lee	Shih-Hsin Tu Chia-Ming Hsieh
15:50-16:10	Multidisciplinary management of locoregional recurrence	Jyh-Cherng Yu	Shou-Tung Chen Hung-Wen Lai
16:10-16:30	Whole brain radiotherapy for breast cancer patients with brain metastases: the role of hippocampal avoidance	Wen-Chi Yang	Cheng-Ying Shiau Hong-Tai Chang
16:30-16:50	Panel discussion	Shin-Cheh Chen / Jeong Eon Lee Jyh-Cherng Yu / Wen-Chi Yang Frank Fu Ou-Yang / Kuo-Ting Lee / Kuo-Hsiu Liao	
16:50-17:00	Award Ceremony & Closing		Ling-Ming Tseng